NACDS Foundation launches patient care database
ALEXANDRIA, Va. The National Association of Chain Drug Stores Foundation has developed a fully searchable resource dedicated to raising the public’s awareness of such topics as medication adherence and other patient services provided by community pharmacy.
NACDS Foundation’s new patient care database was in development for one year before its launch. It aims to archive and track pharmacist-provided patient care activities and services in the community pharmacy setting through its user-friendly, searchable, Web-based database. The database consists of media articles, academic studies, research materials and other resources related to the services provided by pharmacists, including MTM services, vaccination administration, diagnostic screenings and patient counseling. It will help identify trends in pharmacy and allow academia and pharmacy students to study, track and evaluate the short-term and long-term public health benefits of expanded pharmacist-provided health care.
The project was launched successfully under the leadership of the University of Tennessee Center for Medication Therapy Management’s director, Dr. Lawrence M. Brown, PharmD.
“Tremendous collaboration between the NACDS Foundation and the University of Tennessee Center for Medication Therapy Management at the College of Pharmacy made possible this important public resource,” said NACDS Foundation president Edith Rosato. “The patient care database will provide a wealth of knowledge about the multitude of services that community pharmacists deliver to patients that contribute to the advancement of public health.
“With the expansion of community pharmacy’s patient-centric healthcare services, the database is a timely resource that can increase awareness and understanding among patients, medical professionals, researchers, consumers and the media of the healthcare services pharmacists provide the public,” added Rosato.
‘Silent strokes’ linked to kidney failure in diabetics
WASHINGTON Tiny areas of brain damage caused by injury to small blood vessels can signal an increased risk of kidney disease and kidney failure, according to a new study by Japanese researchers.
Publishing in the Journal of the American Society of Nephrology, researchers led by Takashi Uzu of the Shiga University School of Medicine in Otsu, Japan, included 608 patients with Type 2 diabetes, all initially free of symptomatic stroke, heart disease or kidney disease.
Using magnetic resonance imaging scans of the brain, the researchers found that 29% of the patients had the small areas of brain damage, known as silent cerebral infarction or “silent stroke.” A long-term follow-up of the patients found that those with SCI had higher risks of progressive kidney disease, and compared with those who had normal MRI scans, patients with SCI were about 2.5 times more likely to die or develop end-stage kidney disease.
“Silent cerebral infarction may be a new marker to identify patients who are at risk for declining kidney function,” Uzu said in a statement.
Uzu said that small amounts of the protein albumin present in the urine – a condition known as microalbuminuria – are the most important market to predict the progression of kidney disease in diabetics, but decreased kidney function without microalbuminuria is common in those with Type 2 diabetes. According to the new study, diabetics with SCI were more likely to develop serious kidney disease regardless of the protein condition.
Decision Resources: Spiriva to remain clinical gold standard as COPD treatment
WALTHAM, Mass. A drug from Boehringer Ingelheim and Pfizer will retain Decision Resources’ status as a gold standard of treatment for chronic obstructive pulmonary disease through 2018, according to a report released by the market research firm Tuesday.
While some COPD drugs in development held promise, they lacked the same efficacy, safety and tolerability and delivery features of Spiriva (tiotropium bromide), according to the report, titled “Chronic Obstructive Pulmonary Disease: Opportunity Exists for Combination Therapies that Offer Improved Convenience and Outcomes.”
“Our survey of primary care physicians indicates that a drug’s effect on quality of life improvement is the attribute that most influences PCPs’ prescribing decisions in moderate to very severe chronic obstructive pulmonary disease,” Decision Resources analyst Amy Whiting said.